Plain-English translation of NCT06929806 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether , an iron medication given through an IV, can help people with heart failure who have low iron levels. Researchers want to see if this medication reduces hospitalizations and heart-related deaths compared to not receiving IV iron. All participants will continue their regular heart failure care.
Many people with heart failure also have low iron, which can make their symptoms worse and lead to more hospitalizations. This study will help doctors understand whether treating iron deficiency with IV infusions can improve outcomes for these patients.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either receive IV iron infusions or continue with standard care alone. Over several months, you'll visit the clinic or hospital 4–5 times for infusions and blood tests, plus 7 phone or video check-ins. The dose you receive will be based on your weight and iron levels, and you may receive additional doses if needed.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
United States
Large-scale testing
Sponsor
Pharmacosmos A/S
Enrollment target
~1,900 participants
Started
May 2025
Primary completion
December 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Pharmacosmos Clinical and non-clinical Department
Pharmacosmos A/S
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.